AAPGV Ascentage Pharma: Net earnings per share for the last 12 months
Ascentage Pharma Group (AAPGV) is mitigating global risks by diversifying its oncology drugs across Chinese, European, and US markets. Net income per share over the last 12 months reflects profit dynamics, where -2.28 indicates the value of this parameter. Ascentage Pharma Group (AAPGV) focuses on apoptosis inhibition to combat leukemia. Patent protection of unique formulas ensures the holding company maintains high margins within the cancer therapy segment.
%20Net%20earnings%20per%20share%20(EPS%20TTM)&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_AAPGV_-_Ascentage-Pharma-Group_-_Net-earnings-per-share-EPS-TTM "AAPGV Ascentage: Earnings per share for the last twelve months in the range 01/25/2025 - 11/15/2026 | 👁️GURU.Markets👁️")
Summary analytical data breakdowns for Ascentage (AAPGV)
- stock price and consensus target price:
- company stock capitalization data:
- balance sheet net asset value indicators:
- debt level and financial liquidity data:
Total Debt to Capital Ascentage Pharma Group|AAPGV - Long-Term Debt to Capital|Short-Term Debt to Equity ascentage.com|AAPGV - Company Total Debt Obligations|Debts to Book Capitalization Ascentage|AAPGV - Company Long-Term Liabilities|Company Short-Term Debts Ascentage Pharma|Quick Liquidity ascentage.com
- earnings and multiples data:
AAPGV - Company Profit|Future Profit Ascentage Pharma Group|AAPGV - Market Price to Net Income Ratio|Forward P/E Multiple Ascentage Pharma Group International|AAPGV - PEG Multiple|EV/EBITDA Multiple Ascentage Pharma Group Ltd|AAPGV - Operating profit before depreciation charges|Net earnings per share (EPS TTM) Ascentage Pharma|AAPGV - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ascentage.com|AAPGV - Earnings per share increase in current year|Net earnings per share growth forecast for next year Ascentage Pharma Group
- issuer revenue and sales details:
Fundamental company analysis:Ascentage Pharma Group International (AAPGV)
Professional capital evaluates the issuer through the lens of profit generation efficiency per unit of capital. This indicator measures annual net income distributed across all shares, which neutralizes the impact of the total issuance volume. By analyzing the rolling earnings per share trend, an investor can discern the real profitability dynamics without market noise. For Ascentage Pharma Group (AAPGV), this metric reflects the return on implementing robotic platforms in the development of oncology drugs. Steady growth in this metric confirms the financial stability of this high-tech business.
Competitor analysis
ONC - Earnings per share for the last twelve months|HALO - Net earnings per share (EPS TTM)|RevMed (RVMD) - Earnings per share for the last twelve months|Ascentage - Earnings per share for the trailing year|CGON (CG Oncology Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma URGN|Net earnings per share (EPS TTM) BCAX|PSNL: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Erasca Corp ERAS|Delcath Corp (DCTH) - Net earnings per one share for the last twelve months|YMAB - Earnings per share for the last twelve months|Earnings per share for the trailing year AURA (Aura Biosciences, Inc.)|CADL: Net earnings per share (EPS TTM)|Accuray Inc (ARAY) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months SELLAS Life Sciences Group|Net earnings per share (EPS TTM) Actuate Therapeutics, Inc.|Earnings per share for the last twelve months citiusonc.com (CTOR)|Net earnings per share (EPS TTM) TuHURA (HURA)|Net earnings per share (EPS TTM) TARA (protaratx.com)|Earnings per share for the trailing year FATE|WHWK - Earnings per share for the last twelve months|Earnings per share for the trailing year TCRX (tscan.com)|Champions Oncology (CSBR) - Earnings per share for the last twelve months|XBiotech Inc - Earnings per share for the trailing year|Earnings per share for the last twelve months cel-sci.com|OS Therapies (OSTX) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|Earnings per share for the last four quarters ARTV|Adlai Nortye Ltd. - Net earnings per share for the last 12 months|Earnings per share for the trailing year VERU|tempesttx.com - Net earnings per share (EPS TTM)|XLO - Net earnings per share (EPS TTM)|Enochian BioSciences (RENB) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Mural Oncology plc (MURA)|Earnings per share for the last twelve months Kairos Pharma Ltd|Net earnings per share (EPS TTM) OnKure Therapeutics|Net earnings per share for the last 12 months GDTC (w2.cytomed.sg)|Net earnings per share (EPS TTM) Curis Inc. (CRIS)|Earnings per share for the last twelve months Apollomics Inc. APLM|Earnings per share for the trailing year THAR|ADVB - Earnings per share for the last twelve months|GNPX - Net earnings per share (EPS TTM)|CLDI (calidibio.com) - Net earnings per share for the last 12 months|SBFM - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months XBIO|Salarius (SLRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Purple Biotech Ltd. (PPBT)|Earnings per share for the last four quarters AONC|Earnings per share for the last twelve months BeiGene BGNE|CKPT - Net earnings per share for the last 12 months|elevationoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ICAD (icadmed.com)|IKNA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NTBL|VIRX (viracta.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months MorphoSys Inc MOR|Earnings per share for the last twelve months NAYA Bio (NAYA)
